PR100054

SEOUL, South Korea, May 10, 2023 /PRNewswire=KYODO JBN/ --

Gencurix (https://www.gencurix.com/eng/index.php) announced clinical results of

its prognostic test for breast cancer patients at the Global Breast Cancer

Conference 2023. The study, 'Long-term prognostic value of GenesWellBCT score

in Asian women with hormone receptor-positive/HER2- early breast cancer,

involved 366 Korean and Japanese patients and was conducted by Sagara Hospital

and Asan Medical Center. GenesWellBCT test was used for breast cancer

prognosis. The low-risk group showed significantly higher survival rates over

15 years after surgery than the high-risk group, demonstrating the clinical

utility of GenesWellBCT.

Hormone receptor-positive/HER2- breast cancer, which accounts for majority of

early breast cancer cases, has a relatively favorable prognosis compared to

other cancer subtypes. However, there is still a risk of recurrence even after

ten years from surgery. Accurately predicting the risk of recurrence is crucial

for determining individual treatment plans for patients.

Traditional breast cancer prognosis tests provide prediction information for

patient recurrence up to 10years after surgery, but it is still unclear whether

they can accurately predict recurrence beyond 10-years.

The study, conducted on the patients at Asan Medical Center and Sagara

Hospital, evaluated long-term prognostic performance of GenesWellBCT. The

results showed probability of metastasis to other organs for 15-years after

surgery was 6.4% for low-risk group and 36.7% for high-risk group as determined

by GenesWellBCT. Significant differences in survival rates between risk groups

were confirmed in both Korean and Japanese patient groups.

In particular, when early recurrence within 5-years after surgery and late

recurrence between 5 and 15-years after surgery were analyzed separately,

GenesWellBCT was able to predict both types of recurrence significantly.

Moreover, this achievement is significant given existing western breast cancer

diagnostic products have long struggled with accuracy issues for patients under

50-years old. GenesWellBCT has also shown to be effective regardless of age.

GenesWellBCT provides significant information on recurrence for up to 15-years,

surpassing the 10-year predictions provided by existing tests. The study also

highlights the significant differences between GenesWellBCT and others, which

can only predict up to 10 years.

GenesWellBCT is the first breast cancer prognosis diagnostic test in Asia to

receive national government approval. Unlike most Western diagnostic tests have

conducted their clinical trials in western countries, GenesWell BCT has been

verified through multiple clinical trials targeting Asian patients. Gencurix

plans to enter into the Japanese market based on these positive results.

www.gencurix.com/info@gencurix.com

Source: Gencurix